Page 234 - Drug Class Review
P. 234
Page 147 of 205
Drug Effectiveness Review Project
placebo 77% 12% 4% 7% 5% 3% 0% placebo 13.5% 9%
galantamine 32mg 89% 40% 17% 13% 12% 11% 11% Nausea (P = NR); vomiting (P = NR); dizziness (P = NR); headache (P = NR); anorexia (P < 0.001) Loss to follow-up differential high: No (< 15 percentage points difference) galantamine 32mg 25.2% 22%
galantamine 24mg 83% 37% 20% 7% 11% 10% 10% Post randomization exclusions: Yes Overall loss to follow-up: 19.6 % galantamine 24mg 20% 14%
ITT: Yes Yes Yes Yes Good
Final Report Update 1 Authors: Wilcock et al. Year: 2000 ADVERSE EVENTS Overall adverse effects reported: Nausea • Vomiting • Diarrhea • Dizziness • Headache • Anorexia • Significant differences in adverse events: ANALYSIS: ADEQUATE RANDOMIZATION: ADEQUATE ALLOCATION CONCEALMENT: BLINDING OF OUTCOME ASSESSORS: ATTRITION (overall): ATTRITION (treatment specific): Loss to follow-up: Withdrawals due to adverse events: QUALITY RATING: *primary outcome measures Alzheimer's Drugs
